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Abstract
Background: Studies suggest that patients with relapsing–remitting multiple sclerosis (RRMS) who fail to benefit from
a disease-modifying treatment (DMT) may benefit from converting to another DMT class. COPTIMIZE was a 24-month
observational study designed to assess the disease course of patients converting to glatiramer acetate (GA) 20 mg daily
from another DMT and the association of disease characteristics and reasons for converting. This sub-analysis was to
determine if any findings varied by three geographic locations: Latin America (LA), Canada and Western Europe (CWE),
and Eastern Europe (EE).
Methods: A total of 668 patients were included (263 LA, 248 CWE, 157 EE) in an analysis of annualized relapse rate (ARR)
and annualized rate of deterioration (ARD), as well as secondary endpoints including reason for DMT switch and changes
in disability and fatigue scores. Repeated-measures analysis of variance and log transformation were used to analyze ARR
and ARD, whereas the Wilcoxon signed rank test was used for secondary endpoints.
Results: The sub-analysis of treatment outcomes stratified by region showed that Latin American patients had higher
ARR before conversion to GA compared with patients from the other two areas and subsequently experienced the
largest reduction in ARR. Latin American patients also had higher baseline rates of comorbidities and relapses with
incomplete remissions and improved more than those in the other two regions based on measures of fatigue, quality of
life, depression, and cognition scores. Latin American patients also generally had a better perception of the benefits
associated with their conversion to GA in terms of efficacy and adverse events.
Conclusions: These findings indicate that, in RRMS patients, converting to GA is associated with positive treatment
outcomes regardless of geographic location. However, the reasons for converting and the type and degree of any
associated benefits appear to vary depending on various factors, including patients’ geographical location.
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Background
Multiple sclerosis (MS) is a chronic relapsing disorder of
the central nervous system characterized by inflamma-
tion, multifocal demyelination, and neuronal and axonal
damage [1]. The majority of MS patients initially present
with relapsing–remitting MS (RRMS) that frequently
develops to a progressive disease course [1]. The preva-
lence of MS varies according to geographic location from
10 to 20 per 100,000 in Central and South America to >30
per 100,000 in northern Europe and North America [2].
Immunomodulating disease-modifying therapies (DMTs)
have been shown to improve multiple measures of disease
activity in RRMS patients, including the annualized relapse
rate (ARR), proportion of relapse-free individuals, and ac-
cumulation of T2 lesion burden [3–5]. However, these
agents are only partially effective in controlling disease pro-
gression; studies have reported treatment interruption or
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discontinuation because of lack of tolerability, progression
of disability, or inadequate clinical response [6]. Addition-
ally, the development of neutralizing antibodies, specifically
with interferon β products (IFNs) and natalizumab [7], can
interfere with the biologic response [8].
Converting to another DMT class represents one treat-
ment strategy for MS patients with an inadequate re-
sponse to first-line treatments or intolerant side effects
[9]. Expert guidance on the specific steps of a conversion
has been reported [10]; however, the lack of information
on outcomes in different populations [11] results in lim-
ited guidance on regional patient considerations.
The COPTIMIZE study was designed to monitor clin-
ical outcomes after converting from failing or ineffective
DMT therapy for RRMS to glatiramer acetate (GA) in a
prospective way. GA is approved in 57 countries as a
20 mg daily subcutaneous (s.c.) injection for reducing re-
lapse frequency in patients with RRMS. It has long-term
efficacy and safety data, with the longest continuous
treatment exposure of more than 20 years [12, 13]. The
primary results of COPTIMIZE, presented elsewhere
[14], indicate that a conversion to GA is associated with
positive treatment outcomes and that the benefits vary
depending on patients’ reasons for changing. The pri-
mary objective of the present sub-analysis is to deter-
mine whether benefits associated with converting to GA
were affected by therapeutic strategies and patient selec-
tion in different geographic locations: Latin America




Study design, patient eligibility criteria, and conduct of
the COPTIMIZE have been previously reported [14].
Briefly, this post-hoc subgroup analysis attempted to de-
scribe any variation in results that might exist between
three predefined geographical areas: LA (Argentina, Brazil,
Chile, Mexico, Venezuela), CWE (Belgium, Canada,
Denmark, France, Greece, Ireland, Portugal, Netherlands,
Norway, Sweden), and EE (Hungary, Romania, Slovakia).
Countries were grouped into regions based on similarity
of healthcare systems, physician approaches [15], available
treatment options [10, 16], and epidemiological character-
istics of the population (disease prevalence, demographics,
etc.) [2]. All countries investigated in this observational
study reported the use of IFN-β and GA at baseline, with
no anticipated systematic differences between regions.
This study was conducted in accordance with the 18th
World Medical Assembly (Helsinki) recommendations
and amendments, as well as guidelines for Good Epidemi-
ology Practice. The study protocol was approved by the
institutional review boards and independent ethics com-
mittees at all participating study locations in each
individual country; each site ensured all necessary regula-
tory submissions in accordance with local regulations in-
cluding local data protection regulations. All patients
provided informed, written consent according to local in-
dependent review board ruling.
Study endpoints
The primary objective was to assess the disease course
in RRMS patients converting from IFN treatment to GA
as measured by the primary endpoints of ARR and annu-
alized rate of deterioration (ARD) (confirmed progression
of Expanded Disability Status Scale [EDSS]/worsening
mobility scores). Secondary data collected included rea-
sons for DMT conversion, characteristics of patients fail-
ing to benefit from previous DMT, and change in EDSS
and modified fatigue impact scale (MFIS) scores. Also re-
corded were quality of life (QoL) changes following GA
conversion as measured by the Functional Assessment of
Multiple Sclerosis (FAMS), cognition changes as evaluated
by the Paced Auditory Serial Addition Test (PASAT), de-
pression as measured by Centre for Epidemiologic Studies
Depression (CES-D) scale, and change in adverse events
(AEs) following the conversion.
Statistical analyses
Statistical analyses of parameters in this observational
study required comparison of at least two endpoint mea-
sures, pre- and post-GA conversion, with data represented
by descriptive procedures and figures, if necessary. Adjust-
ment for missing data was not required to maintain statis-
tical integrity of the analyses, and annualized rates
(primary endpoints) were calculated for each subject using
all the available data. Other parameters, which provide
additional data for evaluation of the patient status prior to
and following conversion to GA, were reported in a non-
obligatory manner. Tests of significance (signal rank test
and binominal test) were used to measure changes in effi-
cacy parameters from baseline to final examination. ARR
and ARD pre- and post-conversion were analyzed using
repeated measures analysis of covariance using the max-
imum likelihood ratio. Log transformation was imple-
mented to the ARR and ARD to establish if there was a
significant deviation from normality (i.e., P < .001 using
the Shapiro-Wilk test). The Wilcoxon signed rank test




Overall, 672 patients from 148 centers across 19 coun-
tries were enrolled, with 668 patients included in the
analysis (excluding four patients from Taiwan): 263 LA,
248 CWE, and 157 EE patients (Table 1). Patient charac-
teristics were comparable at baseline between regions,
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Table 1 Baseline patient demographics, disease characteristics, and DMT history
Characteristics LA (n = 263) CWE (n = 248) EE (n = 157)
Female gender, n (%) 189 (71.9) 175 (70.6) 108 (68.8)
Mean age, years (± SD) 40.1 (10.1) 43.0 (10.2) 34.7 (8.4)
Patients with comorbidities at recruitment, n (%) 27 (10.3) 19 (7.7) 8 (5.1)
Depression 13 (4.9) 6 (2.4) 1 (0.6)
Anxiety 2 (0.8) 1 (0.4) 1 (0.6)
Hypertension 1 (0.4) 4 (1.6) 2 (1.3)
Patients with concomitant therapies at time of recruitment, n (%) 24 (9.1) 15 (6.1) 7 (4.5)
Psychoanaleptics 14 (5.3) 5 (2.0) 1 (0.6)
Antiepileptics 6 (2.3) 2 (0.8) 1 (0.6)
Thyroid therapy 3 (1.1) 3 (1.2) N/A
Mean disease duration since onset, months (± SD)a 98.0 (82.9) 100.1 (84.4) 92.3 (63.9)
Mean disease duration since diagnosis, months (± SD)b 68.9 (59.6) 72.1 (70.7) 67.9 (48.5)
Mean ARR, events/year (± SD)c 1.0 (0.8) 0.8 (0.6) 0.7 (0.5)
Patients in ARR range, n (%*)
0.00–1.25 166 (67.5) 193 (84.6) 130 (88.4)
1.25–3.25 78 (31.7) 35 (15.4) 17 (11.6)
>3.25 2 (0.8) 0 (0.0) 0 (0.0)
Data unavailable 17 20 10
Clinical type of MS, n (%d)
RRMS with incomplete remissions 171 (67.6) 117 (47.6) 91 (59.1)
RRMS with complete remission 80 (31.6) 122 (49.6) 62 (40.3)
Clinically isolated syndrome 0 (0.0) 0 (0.0) 1 (0.6)
Other 2 (0.8) 7 (2.8) 0 (0.0)
Data unavailable 10 2 3
Diagnosed with MS by criteria, n (%d)
McDonald 217 (83.8) 194 (78.5) 143 (92.3)
Poser 42 (16.2) 53 (21.5) 12 (7.7)
Data unavailable 4 1 2
Mobility, n (%d)
Asymptomatic 45 (19.8) 46 (20.0) 20 (14.9)
Able to walk unaided for >500 m 96 (42.3) 126 (54.8) 112 (83.6)
Able to walk unaided for <500 m 30 (13.2) 27 (11.7) 2 (1.5)
Walking with bilateral support 13 (5.7) 9 (3.9) 0 (0.0)
Walking with unilateral support 33 (14.5) 18 (7.8) 0 (0.0)
Need of a wheelchair outdoors 10 (4.4) 4 (1.7) 0 (0.0)
Data unavailable 36 18 23
Mean EDSS score (± SD)e 3.5 (2.2) 2.8 (1.9) 2.6 (1.0)
Mean CES-D score (0–60) (± SD)f 16.0 (11.7) 16.0 (10.3) 20.6 (19.5)
Mean MFIS score (0–84) (± SD)g 32.3 (19.7) 31.4 (19.1) 33.7 (27.9)
Mean FAMS score (0–176) (± SD)h 109.4 (37.8) 100.8 (34.3) 77.7 (59.4)
Mean PASAT score (0–60) (± SD)i 35.6 (13.6) 36.7 (15.7) 51.8 (5.9)
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excluding EE patients, who were younger and reported
fewer comorbidities and concomitant medications than
LA and CWE patients. Baseline disease characteristics
that were similar across regions (Table 1) included dis-
ease duration from onset, diagnosis, and mean ARR.
Distribution of baseline ARR score varied slightly, with
the majority of patients experiencing between 0 and 1.25
events/year. LA patients reported the highest disability
(baseline EDSS) and the highest frequency of RRMS
with incomplete remissions. At baseline, the majority of
patients had received one previous DMT regimen in one
class of agents (Table 1). Reports of flu-like symptoms
were the most common reason for converting to GA.
The majority of patients in all regions were converted
from IFN-β therapy.
Annualized relapse rate
ARR was significantly decreased in all groups following
the conversion to GA (Fig. 1). LA patients, who had the
highest baseline ARR rate, also had the greatest ARR
Table 1 Baseline patient demographics, disease characteristics, and DMT history (Continued)
Mean observation duration, months (± SD)j 20.5 (6.3) 18.6 (7.7) 19.2 (7.8)
Number of DMT classes used (%) (converters only)
1 206 (85.5) 201 (83.4) 143 (92.9)
2 32 (13.3) 38 (15.8) 10 (6.5)
3 3 (1.2) 2 (0.8) 1 (0.6)
Non-converters 22 7 3
Previous type and mode of IFN-β used, %k
IFN-β-1a (i.m.) 30.3 36.0 47.4
IFN-β-1b (s.c.) 30.3 25.9 30.5
IFN-β-1a (s.c.) 35.5 30.7 21.4
Reason for conversion to GA, n (%)l
Lack of previous DMT efficacy 171 (71.0) 78 (32.4) 92 (59.7)
Presence of neutralizing antibodies 1 (0.4) 44 (18.3) 2 (1.3)
Intolerable adverse events associated with previous DMT 98 (40.7) 132 (54.8) 55 (35.7)
Flu–like symptoms 67 (27.8) 73 (30.3) 40 (26.0)
Subjective 29 (12.0) 37 (15.4) 17 (11.0)
Skin reactions 15 (6.2) 14 (5.8) 20 (13.0)
Blood work 7 (2.9) 18 (7.5) 4 (2.6)
Others 21 (8.7) 39 (16.2) 4 (2.6)
Not specified 1 (0.4) 1 (0.4) 0 (0.0)
Other 8 (3.3) 21 (8.7) 36 (23.4)
Non-converters 22 7 3
Discontinuation of GA, n (%) 66 (25.1) 77 (31.1) 30 (19.1)
Perceived lack of efficacy by physician 19 (7.2) 7 (2.8) 16 (10.2)
Perceived lack of efficacy by patient 7 (2.7) 14 (5.7) 6 (3.8)
Adverse events 9 (3.4) 17 (6.9) 4 (2.5)
Lost to follow-up 14 (5.3) 24 (9.7) 2 (1.3)
Other 15 (5.7) 8 (3.2) 3 (1.9)
aMissing data in 24 LA, 28 CWE, and 5 EE patients
bMissing data in 15 LA, 21 CWE, and 4 EE patients
cMissing data in 7 LA, 2 CWE, and 3 EE patients
dAdjusted percentage of patients with data available
eMissing data in 55 LA, 9 CWE, and 8 EE patients
fMissing data in 116 LA, 103 CWE, and 150 EE patients
gMissing data in 113 LA, 118 CWE, and 150 EE patients
hMissing data in 55 LA, 9 CWE, and 8 EE patients
iMissing data in 197 LA, 103 CWE, and 150 EE patients
jMissing data in 11 LA, 17 CWE, and 10 EE patients
kMissing data in 32 LA, 20 CWE, and 3 EE patients
lAdjusted percentage of patients with data available. Patients were allowed to cite ≥1 reason for conversion to GA. Therefore, the percentage may exceed 100 %
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reduction (1.05 ± 0.78 pre-conversion to 0.34 ± 0.86
post-conversion; P < .0001, Shapiro-Wilk test). ARR went
from 0.73 ± 0.58 to 0.34 ± 0.84 (P < .0001) in CWE
patients and 0.71 ± 0.50 to 0.24 ± 0.92 (P < .0001) in
EE patients.
Disease progression
In total, 499 patients had ≥1 EDSS assessment after
baseline examination, with the overall population show-
ing a significant increase in EDSS score (i.e., progression
to worse disability) from 2.9 at baseline to 3.02 at final
follow-up, post-switch (P = .0256). There was a significant
difference between regions in the degree of change in
EDSS score while on GA therapy (P = .0230, Wilcoxon
signed-rank test), driven by a significant increase in CWE
patients’ EDSS score of 0.26 ± 1.18 (P = .0016). Neither LA
nor EE patients had significant changes in mean EDSS
score from baseline. Improved (i.e., numerically lowered)
EDSS scores were seen in 32.5 %, 24.4 %, and 33.8 % of
LA, CWE, and EE patients, respectively. There was no
change from baseline in 35.8 %, 34.9 %, and 41.2 %,
respectively. Deterioration was reported in 31.8 %, 40.7 %,
and 25.0 %, respectively.
Disease activity
Disease activity while receiving GA varied. LA patients re-
ported the highest incidence of frequent exacerbations
and of fast progression of MS (Table 2). Fewer LA patients
reported rarely experiencing exacerbations (27.9 %, vs.
43.5 % CWE and 66.0 % EE patients).
Change in mobility
The majority of patients showed no change in mobility
scores (63.4 %, 62.8 %, and 67.5 % of LA, CWE, and EE
patients, respectively). Mobility scores improved in
17.1 % LA and 18.9 % CWE patients, with a significant
improvement in 23.0 % of EE patients (P = .0079). Mo-
bility scores deteriorated in 19.4 %, 18.4 %, and 9.5 % of
LA, CWE, and EE patients, respectively. Data were miss-



































Fig. 1 Reduction of annualized relapse rate by geographic region. aP < .0001 vs. baseline. *The overall population size does not each the sum of
the three individual regions due to four patients in Taiwan that excluded from the regional analysis. ARR annualized relapse rate
Table 2 MS disease activity over the 2-year study period
Patients, n (%) LA CWE EE
(n = 251) (n = 246) (n = 153)
Stable MS (Stage 1) 37 (14.7) 47 (19.1) 22 (14.4)
Rare exacerbations (≤1 per year, Stage 2a) 70 (27.9) 107 (43.5) 101 (66.0)
Slow progression (≤0.5 EDSS points per year, Stage 2b) 48 (19.1) 35 (14.2) 6 (3.9)
Frequent exacerbations (>1 per year, Stage 3a) 80 (31.9) 43 (17.5) 21 (13.7)
Fast progression (>0.5 EDSS points per year, Stage 3b) 11 (4.4) 3 (1.2) 1 (0.7)
Not classified/not available 5 (2.0) 11 (4.5) 2 (1.3)
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Secondary endpoints
In LA patients, there was a significant improvement in the
mean difference in MFIS score from baseline (6.9 ± 15.4;
P < .0001) (Fig. 2). EE patients and CWE patients experi-
enced a nonsignificant increase from baseline of 6.7 ± 18.2
and 0.4 ± 13.6, respectively.
Only LA patients showed a significant change in QoL,
with an improvement in mean FAMS score of 18.5 ±
46.5 from baseline (P = .0008). CWE patients had a mean
FAMS increase of 0.6 ± 20.5, while EE patients showed a
decrease of 2.3 ± 8.8 (Fig. 3).
LA patients reported a significant improvement in de-
pression symptoms, with a decrease in mean CES-D
score of 4.6 ± 10.9 (P < .0001) (Fig. 2). CWE patients
showed a numerical increase in mean CES-D score of
1.7 ± 9.9, while EE patients showed a decrease of 2.4 ±
10.8. These changes were not statistically significant.
Patients from all regions showed an improvement in
mean PASAT (cognition) scores (Fig. 2). LA patients had
the greatest improvement, with a statistically significant
mean increase of 6.3 ± 9.1 in PASAT score (P = .0030).
CWE patients also showed a statistically significant
mean increase of 3.8 ± 9.6 (P = .0024), while EE patients
had a smaller mean increase of 0.8 ± 5.3 (NS).
LA patients reported the highest efficacy with GA than
the previous drug (70.0 %; P < .0001), followed by EE
and CWE patients (42.4 % and 41.6 %, respectively; both
P < .0001). LA patients reported the lowest percentage of
“feeling worse” on GA therapy (3.9 %), with EE patients
reporting the highest percentage (15.2 %), followed by
CWE patients (6.1 %). There was no change in percep-
tion of efficacy in 26.2 %, 52.2 % and 42.4 % of LA,



















































Canada and WE (n=130)
Eastern Europe (n=7)
Latin America (n=147)
Canada and WE (n=145)
Eastern Europe (n=7)
Latin America (n=20)





Fig. 2 Change in fatigue, depression, and cognition scores by geographic region. aP < .0001 for Latin America vs. Canada/Western Europe at final
follow-up. bP < .0001 for change from baseline. cP < .0001 for change from baseline. dP = .0030 for change from baseline. eP = .0024 for change




























Canada and Western Europe (n=145)
Eastern Europe (n=7)
a,b
Fig. 3 Change in quality of life score by geographic region. aP = .0012
for Latin America vs. Canada/Western Europe at final follow-up.
bP = .0008 for change from baseline. FAMS Functional Assessment
of Multiple Sclerosis
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Safety
AEs reported in all three regions are listed in Table 3.
Patients from all regions experienced statistically signifi-
cant improvements in AEs with GA use (P < .0001).
Discussion
Converting to another class of immunomodulatory ther-
apy represents one treatment strategy in MS patients
who fail to respond adequately to first-line treatments
[10]. However, this strategy may not always be beneficial
because of geographical variations in treatment regimens
and therapeutic strategies. For example, GA and IFN-β
are typically the first-line treatment options in MS treat-
ment algorithms, regardless of the geographical region
[11]. However, some LA neurologists prescribe azathio-
prine because of limited DMT access or because the
drugs are unavailable on healthcare plans [16, 17]. Ex-
pert guidance on the specific steps of a conversion have
begun to be published, suggesting a conversion in ther-
apy may be considered when there is a high level of
concern about relapse rates, progression of MS and
magnetic resonance imaging outcomes, a medium
level of concern about any two factors, or a low level
of concern about all three factors [10]. The general
nature of the guidelines is due to inconsistent results
with converting.
In this sub-analysis of the COPTIMIZE trial, convert-
ing to GA was well tolerated, reduced disease progres-
sion and activity, and improved other secondary
endpoints in patients across all three regions to varying
degrees. LA patients experienced the largest reduction
in ARR; however, their baseline ARR was much higher
than CWE and EE patients. Ultimately, all three regions
reached similar ARR. LA patients had higher baseline
rates of comorbidities and incomplete previous remis-
sions than the other two regions, as well as significant
improvements in QoL, depression, fatigue, and cognition
scores. They also had a better perception of the benefits
of a GA conversion in terms of efficacy and AEs than
CWE and EE patients.
These discrepancies may be due to differences in
healthcare standards and environmental factors between
Table 3 Adverse events (AEs)
Patients, events/patients (%a) LA (n = 263) CWE (n = 248) EE (n = 157)
Most common AEs by preferred term
Dyspnea 5/4 (1.5) 4/3 (1.2) 1/1 (0.6)
Syncope 2/2 (0.8) 2/2 (0.8) 0/0 (0.0)
Injection site reaction 2/2 (0.8) 8/8 (3.2) 0/0 (0.0)
Injection site pain 2/2 (0.8) 14/10 (4.0) 0/0 (0.0)
Injection site induration 1/1 (0.4) 5/5 (2.0) 0/0 (0.0)
Fatigue 1/1 (0.4) 3/3 (1.2) 0/0 (0.0)
Arthralgia 1/1 (0.4) 3/3 (1.2) 0/0 (0.0)
Rash 0/0 (0.0) 2/2 (0.8) 2/2 (1.3)
Anxiety 0/0 (0.0) 1/1 (0.4) 1/1 (0.6)
Most common AE classified by system organ class
General disorders and administration site conditions 16/13 (4.9) 55/32 (12.9) 5/4 (2.6)
Nervous system disorders 10/10 (3.8) 9/8 (3.2) 0/0 (0.0)
Respiratory, thoracic, and mediastinal disorders 7/6 (2.3) 4/3 (1.2) 0/0 (0.0)
Severity of AE, events/patients
Mild 19/12 (4.6) 40/28 (11.3) 0/0 (0.0)
Moderate 22/12 (4.6) 62/38 (15.3) 5/5 (3.2)
Severe 13/6 (2.3) 14/9 (3.6) 5/3 (1.9)
Data unavailable 4/2 (0.8) 7/5 (2.0) 2/2 (1.3)
Patient-reported assessment of AEs after glatiramer acetate treatmentb
Improved with glatiramer acetate 209 (80.4) 162 (66.1) 58 (38.4)
Same with glatiramer acetate 41 (15.8) 62 (25.3) 87 (57.6)
Worse with glatiramer acetate 10 (3.9) 21 (8.6) 6 (4.0)
Data unavailable 3 3 6
aPercentage reported as the proportion of patients experiencing events
bAdjusted percentage of patients with data available
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the different regions. For example, the US, Canada, and
LA have clinical treatment guidelines that vary in the
topics discussed and the use of GA, IFN-β, natalizumab,
dalfampridine, and fingolimod [10, 16–18]. Also, it is pos-
sible that patients from different regions may have differ-
ent epidemiological characteristics and comorbidities [16].
These regional differences cannot be adjusted in such a
study, where the observational, non-interventional design
carries inherent analytical limitations.
Now that consensus guidelines have defined a subopti-
mal treatment response, and neurodegenerative activity
has been identified even in early stages of disease [19,
20], converting to another DMT class represents a lo-
gical treatment strategy in patients who fail to respond
adequately to first-line treatments. Our results suggest
that more attention is required regarding the importance
of establishing formal conversion algorithms that ac-
count for geographic variability, ensuring that all pa-
tients who could benefit from such an approach are
managed in a timely and optimal manner.
Despite study limitations, our observations emphasize
the importance of changing a therapy regimen, in par-
ticular IFN-based, to improve efficacy and/or overcome
treatment intolerance that would otherwise compromise
compliance. This is in alignment with previous studies
of this strategy [9, 21].
Conclusions
All patients experienced significant improvements in
ARR regardless of geographic region. There were differ-
ences between regions in patients’ baseline parameters,
comorbidities, and reasons for converting to GA treat-
ment. The evolution of guidelines regarding suboptimal
treatment response and DMT conversion has the poten-
tial to affect strategies for monitoring and treating pa-
tients across all geographies and to improve clinical and
patient-reported outcomes.
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